BeyondSpring Says It Will Host Virtual R&D Day To Discuss New Plinabulin Development Strategy For Cancer And Updates For Seed Therapeutics

BeyondSpring Says It Will Host Virtual R&D Day To Discuss New Plinabulin Development Strategy For Cancer And Updates For Seed Therapeutics

BenzingaMay 3 19:24

BeyondSpring Reports FY23 Loss Per Share Of $(0.54) Vs. $(0.85) Last Year

As of December 31, 2023, the Company had cash, cash equivalents, restricted cash, and short-term investments of $17.9 million.Net loss attributable to the Company was $(21.0) million for the year ende

BenzingaApr 30 05:35

BeyondSpring Files 2023 Annual Report on Form 20-F

FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer

GlobeNewswireApr 30 05:30

Press Release: BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results

BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today provided a business update and reported results for the year ended December 31, 2023.

Dow JonesApr 30 05:30

IBio, Mesoblast, Kodiak Sciences Among Healthcare Movers

Seeking AlphaMar 28 22:01

BeyondSpring Says First Patient Dosed in Phase 2 Trial of Lung Cancer Combination Treatment

BeyondSpring (BYSI) said Monday that the first patient has been dosed in a phase 2 investigator-initiated trial of pembrolizumab, plinabulin plus etoposide/platinum for first-line extensive-stage smal

MT NewswiresMar 25 22:28